XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities    
Net loss $ (43,007) $ (45,109)
Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities    
Depreciation and amortization 2,351 2,699
Amortization of lease right-of-use assets 1,851 1,499
Loss on extinguishment of liabilities, net   3,004
Share-based compensation expense 4,292 3,884
Change in fair value of warrant liability, net 1,332  
Provision for doubtful accounts 467 (27)
Accrued interest, amortization of debt issuance costs and other 3,954 5,011
Inventory excess and obsolescence 115 837
Impairment loss on intangible assets 20 81
Changes in operating assets and liabilities:    
Accounts receivable (1,178) (765)
Other current assets 1,798 1,868
Other long-term assets (26) (3,645)
Accounts payable and other accrued liabilities (247) (646)
Deferred revenue (395) (985)
Tenant improvement allowances received 18,323  
Current and long-term operating lease liabilities (237) (730)
Net cash and cash equivalents and restricted cash used in operating activities (10,587) (33,024)
Cash flows from investing activities    
Purchase of property and equipment (19,935) (1,368)
Patent costs and intangible asset acquisition, net (126) (179)
Net cash and cash equivalents and restricted cash used in investing activities (20,061) (1,547)
Cash flows from financing activities    
Proceeds from the issuance of common stock 15,316 17,966
Proceeds from issuance of common stock under employee stock purchase plan 643 355
Proceeds from exercise of stock options 90 149
Payment of contingent consideration (7,591) (8,691)
Proceeds from term loan and notes payable   15,102
Repayment of term loan and notes payable (36) (5,038)
Payment of debt issuance costs (833) (2,249)
Deferred offering costs   (129)
Equity financing costs (61) (407)
Other (127) (24)
Net cash and cash equivalents and restricted cash provided by financing activities 7,401 17,034
Net decrease in cash and cash equivalents and restricted cash (23,247) (17,537)
Cash, cash equivalents, and restricted cash ‑ beginning of period 43,174 32,798
Cash, cash equivalents, and restricted cash ‑ end of period 19,927 15,261
Supplemental cash flow information:    
Common stock issued for deferred offering costs   600
Deferred offering costs amortized against Additional paid-in capital   52
Original issue discount associated with Promissory Note One   1,025
Issuance of Perceptive Warrants 674  
Equity financing costs included in accounts payable and other accrued liabilities   14
Operating lease right-of-use assets obtained in exchange for lease liabilities at adoption of ASC 842   1,269
Operating lease right-of-use assets obtained in exchange for lease liabilities 867 3,694
Finance lease right-of-use assets obtained in exchange for lease liabilities 773 123
Cash paid for interest 3,241 473
Purchases of property & equipment included in Accrued liabilities $ 824 69
Patent costs included in Accrued liabilities   $ 10